Everest Medicines (HKSE:01952) Interest Coverage: 0 (At Loss) (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01952 Everest Medicines Ltd HKSE:01952
41 GF Score
Price HK$27.60
GF Value HK$295.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Interest Coverage?

Everest Medicines HKSE:01952 +1.85% 41 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates HKSE:01952 with a GF Score™ of 41/100 and a GF Value™ of HK$295.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, Everest Medicines ranks worse than 265957.18% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Everest Medicines's Operating Income for the six months ended in Dec. 2025 was HK$-67 Mil. Everest Medicines's Interest Expense for the six months ended in Dec. 2025 was HK$-13 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Everest Medicines's Interest Coverage or its related term are showing as below:


HKSE:01952's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Everest Medicines  (HKSE:01952) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Everest Medicines Interest Coverage Related Terms


Everest Medicines Interest Coverage Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Everest Medicines Interest Coverage Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:01952 vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Everest Medicines's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Interest Coverage falls into.


HKSE:01952
41GF Score
Everest Medicines Ltd HKSE:01952
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Everest Medicines's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Everest Medicines's Interest Expense was HK$-26 Mil. Its Operating Income was HK$-409 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$920 Mil.

Everest Medicines did not have earnings to cover the interest expense.

Everest Medicines's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the six months ended in Dec. 2025, Everest Medicines's Interest Expense was HK$-13 Mil. Its Operating Income was HK$-67 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$920 Mil.

Everest Medicines did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Everest Medicines (HKSE:01952) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Everest Medicines and its competitors. According to the industry distribution chart, Everest Medicines ranks #999999 out of 376 companies in the Biotechnology industry.
Is Everest Medicines' Interest Coverage too high?
Everest Medicines' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Everest Medicines ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Everest Medicines has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #999999 out of 376 companies for Interest Coverage. This places Everest Medicines in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Everest Medicines and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$295.50, compared to a current price of HK$27.60 — trading 90.7% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Everest Medicines' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$27.60 is trading 90.7% below its estimated GF Value™ of HK$295.50. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01952:

  • Interest Coverage: 0 (At Loss)
  • GF Value™: HK$295.50 vs. price of HK$27.60 (90.7% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
41GF Score

Get the complete analysis for HKSE:01952

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.60
Price
HK$295.50
GF Value